LabCorp Schedule

LabCorp Schedule - information about LabCorp Schedule gathered from LabCorp news, videos, social media, annual reports, and more - updated daily


Recent LabCorp Schedule News

| 48 days ago
- PAMA 2018 Medicare Payment Rates for lab testing,” LabCorp (NYSE: LH), a leading global life sciences - comprehensive clinical laboratory and end-to-end drug development services. LabCorp (NYSE: LH), an S&P 500 company, - ended December 31, 2016, and subsequent Forms 10-Q, under the Clinical Lab Fee Schedule (CLFS - and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to work with the SEC including the -

Related Topics:


Other LabCorp information related to "schedule"

Page 10 out of 54 pages
- . The Company's acquisition of MEDTOX on the Company's operations in 2013. Changes in governmental regulations will have a significant - faces significant revenue impacts in 2013 as compared with 2011 was negative 0.95% and the Middle - 2012 Revenue Per Requisition Routine Testing $ 37.68 Genomic and Esoteric - in the Company's routine testing. These fee schedule reductions became effective on patient visits - other major holidays. Results of successive quarters may reduce net revenues and -

Related Topics:

Page 9 out of 128 pages
- was applied after the adjustment of the fee schedule by 2%, effective January 1, 2013. During 2014, the Company experienced a - regulatory and administrative requirements. The Company believes that Covance Drug Development competes favorably in the clinical laboratory business - March 2010, comprehensive health care reform legislation, the Patient Protection and Affordable Care Act (" - acts to prevent the cut, as diagnostic testing continues to shift away from 2011 through 2015. On April 1, -

Related Topics:

Page 26 out of 128 pages
- 2009 CPI update to update the CLFS thereafter. During 2014, the Company experienced a $6.0 million reduction in the CPI update of the CLFS from year to begin annual evaluations of 2011, which includes certain payments to diagnostic laboratories) - Services determines are prohibited from paying more than the Medicare fee schedule limit for covered tests performed on - (which became effective April 1, 2013. Pursuant to the Medicare Improvements for Patients and Providers Act of -
Page 21 out of 151 pages
- alternative payment models in the years 2013 through 2016 and 2017. Based on the Company's net earnings and - and regulations (or in 2015 and Palmetto implemented a revised Drugs of Abuse Local Coverage Policy which impacted the handling of years 2016-2019, - codes and a number of those plans. Index to patients with specified medical conditions or diagnoses, replacing local - is applied to calculate the fee schedule conversion factor, would no longer pay for tests that previously have -
Page 20 out of 128 pages
- research and development investments. Other Institutions. Covance Drug Development provides its acquisition of the Company's consolidated net - and character. During the year ended December 31, 2014, no client or group of clients under the - party payer is derived from core and specialty testing to pay on a fee-for -service basis. Hospitals. With its services, on - private patients. Payers Testing services are typically billed monthly at the Company's patient fee schedule, net of -
Page 10 out of 151 pages
- Term Care (Ministry) determines who are unwilling or unable to pay. Agings of 2014 (ABLE Act). For client billing, third - providers to participate in the collection of approximately 93.6% of its focus on test requisitions. Bad debt expense is expected to - related issues by the Physician Fee Schedule (PFS). This is typically generated monthly, whereas patient and third - covers the cost of electronic test ordering. This system generates bills to result in a future net reduction in -

Related Topics:

Page 15 out of 151 pages
- stock they also refer less time-sensitive procedures, less frequently needed testing - and negotiation by physicians on behalf of the Company's testing capabilities and in direct negotiation of the products - basis that is billed at the Company's patient fee schedule, net of any such tests on a set - reimbursement rules. These clients typically pay on a negotiated feefor-service basis or based - . Index Clients The Company provides testing and drug development services to a broad range -
Page 28 out of 58 pages
- 2008 43.6% 19.2% 11.3% 7.4% 4.4% 4.1% 8.2% 1.5% 0.3% Revenue is recognized for services rendered when the testing process is complete and - sales considered necessary to limitations on benefits and pay imposed on a negotiated monthly contractual rate - receivables. These adjustments are recorded at the Company's patient fee schedule, net of any negotiated discount. - Company has a formal process to be representative of the majority of LabCorp. Bad debt expense is maintained for the Company. -

Related Topics:

Page 32 out of 66 pages
- paid under the Employee Retirement Income Security Act of LabCorp. LABORATORY CORPORATION OF AMERICA Management's Discussion and - and Allowance for Doubtful Accounts Revenue is recognized for services rendered when the testing process is complete and test - 's third-party sales are recorded at the Company's patient fee schedule, net of sale. Adjustments to the Company's results of operations in part to limitations on benefits and pay imposed on behalf of their respective aging categories -
Page 20 out of 58 pages
- at December 31, 2013 and 2012: Days Outstanding 0 - 30 31 - 60 61 - - 270 271 - 360 Over 360 2013 46.4% 19.3% 11.5% 7.1% 3.4% 3.8% 7.3% 0.9% 0.3% 2012 48 - . The following table presents the percentage of the Company's net accounts receivable outstanding by aging category - are recorded at the transaction level at the Company's patient fee schedule, net of any discounts negotiated - allowance for doubtful accounts Revenue is recognized for services rendered when the testing process is complete and -
Page 28 out of 60 pages
- ned benefit retirement plan (the "Company Plan"). Fee-for services rendered when the testing process is complete and test - These discounts are recorded at the transaction level at the Company's patient fee schedule, net of any negotiated discount. Accounts - part to limitations on benefits and pay imposed on a fee-for each transaction as the age of the underlying receivables, - time of sale based on years of credited service and compensation earned while an employee of LabCorp. -
Page 58 out of 151 pages
- adjustments based on behalf of services, this is complete and test results are recorded using output measures that - using an actual or contracted fee schedule at the Company's patient fee schedule, net of any negotiated discount. - services to be the same at the time of sale based on the nature of the work required under long-term contracts, - agreed to the service provided. While a project is required to pay CDD for each transaction as an adjustment to the estimated payment -
Page 12 out of 58 pages
- with their discovery, preclinical and clinical drug development programs. The effective combination of Tandem's - dominated headlines, we introduced online appointment scheduling and self-check-in kiosks - . Net sales increased 10.7 percent to fuel a new era of growth for tailoring drugs - growth that we achieved in companion diagnostic testing during 2008 when, despite economic headwinds, - convenience tools throughout 2009. LabCorp touches millions of patients, tens of thousands of doctors -

Related Topics:

Page 17 out of 52 pages
- and Allowance for Doubtful Accounts Revenue is complete and test results are maintained for 15 The adoption of the authoritative guidance did not have an impact on December 31, 2011. The Company's Audit Committee periodically reviews the Company's significant accounting policies. Fee-for consolidation of variable interest entities. For the remaining third-party - of contingent assets and liabilities at the Company's patient fee schedule, net of any negotiated discount. These -
Page 17 out of 52 pages
- future events. Adjustments to the estimated payment amounts are recorded on a fee-for-service basis at the time of final collection and - recorded using an actual or contracted fee schedule at the Company's patient fee schedule, net of operations or cash flows. - Financial Condition and Results of Operations (in millions) In June 2011, the FASB issued authoritative guidance on the presentation of - Medicaid. Bad debt expense is complete and test results are reported to estimate and review the -

Related Topics

Timeline

Related Searches